MARLBOROUGH, Mass.,
March 2, 2016 /PRNewswire/
-- Hologic, Inc. (Nasdaq: HOLX) announced today that
Christopher J. Coughlin has joined
the Company's Board of Directors. Mr. Coughlin was elected to
the Board at the Company's 2016 Annual Meeting of Stockholders,
along with nine existing Directors who were re-elected.
Mr. Coughlin, who in December was named "Director of the Year"
by the National Association of Corporate Directors, has extensive
senior leadership experience, including as the former Chief
Financial Officer of Tyco International. He has held
executive operating and financial positions at the Interpublic
Group, Pharmacia and Nabisco International. Mr. Coughlin
currently serves on the boards of Allergan (formerly Actavis),
Alexion Pharmaceuticals and Dun & Bradstreet, where he is
Chairman of the Board. He previously served on the boards of
Covidien, Dipexium Pharmaceuticals, Forest Laboratories, the
Interpublic Group, Monsanto and Perrigo.
"It is a pleasure to welcome Chris to Hologic's Board," said
Steve MacMillan, the Company's
Chairman, President and Chief Executive Officer. "He is a
proven business leader who brings a strong track record of value
creation. His depth of experience in executive leadership
roles within complex corporate organizations, his financial
background, and his experience on public company boards will
contribute critical insights in Hologic's efforts to generate
sustainable growth and shareholder value."
About Hologic
Hologic, Inc. is a leading developer, manufacturer and supplier
of premium diagnostic products, medical imaging systems and
surgical products. The Company's core business units focus on
diagnostics, breast health, GYN surgical, and skeletal
health. With a unified suite of technologies and a robust
research and development program, Hologic is dedicated to The
Science of Sure. For more information on Hologic, visit
www.hologic.com.
Forward-Looking Statements
This news release contains forward-looking information that
involves risks and uncertainties, including statements about the
Company's plans, objectives, expectations and intentions, and
statements regarding the Company's Board of Directors. These
forward-looking statements are based on assumptions made by the
Company as of this date and are subject to known and unknown risks
and uncertainties that could cause actual results to differ
materially from those anticipated. These risks include, but
are not limited to, the risk that the Company may not be able to
attract and retain qualified Board members or executives.
These risks are not exhaustive. Other factors that could
adversely affect the Company's business and prospects are described
in the filings made by the Company with the SEC. The Company
expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any such statements presented
here to reflect any change in expectations or any change in events,
conditions or circumstances on which any such statements are
based.
Contact
Michael Watts
Vice President, Investor Relations and Corporate Communications
(858) 410-8588
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/chris-coughlin-elected-to-hologic-board-of-directors-300229079.html
SOURCE Hologic, Inc.